198 related articles for article (PubMed ID: 30291223)
21. Evolving applications of lenalidomide in the management of anemia in myelodysplastic syndromes.
List AF
Cancer Control; 2006 Dec; 13 Suppl():12-6. PubMed ID: 17242662
[TBL] [Abstract][Full Text] [Related]
22. Long-term transfusion independence in del(5q) MDS patients who discontinue lenalidomide.
Giagounidis AA; Kulasekararaj A; Germing U; Radkowski R; Haase S; Petersen P; Göhring G; Büsche G; Aul C; Mufti GJ; Platzbecker U
Leukemia; 2012 Apr; 26(4):855-8. PubMed ID: 21960245
[No Abstract] [Full Text] [Related]
23. Lenalidomide: targeted anemia therapy for myelodysplastic syndromes.
List AF; Baker AF; Green S; Bellamy W
Cancer Control; 2006 Dec; 13 Suppl():4-11. PubMed ID: 17242661
[TBL] [Abstract][Full Text] [Related]
24. Efficacy of lenalidomide in a patient with myelodysplastic syndrome with isolated del(5q) and JAK2V617F mutation.
Nomdedeu M; Maffioli M; Calvo X; Martínez-Trillos A; Baumann T; Díaz-Beyá M; Aguilar JL; Rozman M; Costa D; Esteve J; Cervantes F; Colomer D; Nomdedeu B
Leuk Res; 2011 Sep; 35(9):1276-8. PubMed ID: 21764129
[No Abstract] [Full Text] [Related]
25. Validation of the IPSS-R in lenalidomide-treated, lower-risk myelodysplastic syndrome patients with del(5q).
Sekeres MA; Swern AS; Fenaux P; Greenberg PL; Sanz GF; Bennett JM; Dreyfus F; List AF; Li JS; Sugrue MM
Blood Cancer J; 2014 Aug; 4(8):e242. PubMed ID: 25171203
[No Abstract] [Full Text] [Related]
26. Emergence and evolution of
Lodé L; Ménard A; Flet L; Richebourg S; Loirat M; Eveillard M; Le Bris Y; Godon C; Theisen O; Gagez AL; Cartron G; Commes-Maerten T; Villemagne B; Luycx O; Godmer P; Pellat-Deceunynck C; Soussi T; Béné MC; Delaunay J; Peterlin P
Haematologica; 2018 Apr; 103(4):e143-e146. PubMed ID: 29269520
[No Abstract] [Full Text] [Related]
27. Dual pyroptotic biomarkers predict erythroid response in lower-risk non-del(5q) myelodysplastic syndromes treated with lenalidomide and recombinant erythropoietin.
Wang C; McGraw KL; McLemore AF; Komrokji R; Basiorka AA; Al Ali N; Lancet JE; Padron E; Kosmider O; Fontenay M; Fenaux P; List AF; Sallman DA
Haematologica; 2022 Mar; 107(3):737-739. PubMed ID: 34320786
[No Abstract] [Full Text] [Related]
28. Lenalidomide in lower-risk myelodysplastic syndromes with karyotypes other than deletion 5q and refractory to erythropoiesis-stimulating agents.
Sibon D; Cannas G; Baracco F; Prebet T; Vey N; Banos A; Besson C; Corm S; Blanc M; Slama B; Perrier H; Fenaux P; Wattel E;
Br J Haematol; 2012 Mar; 156(5):619-25. PubMed ID: 22211483
[TBL] [Abstract][Full Text] [Related]
29. Single-cell transcriptional profile of CD34+ hematopoietic progenitor cells from del(5q) myelodysplastic syndromes and impact of lenalidomide.
Serrano G; Berastegui N; Díaz-Mazkiaran A; García-Olloqui P; Rodriguez-Res C; Huerga-Dominguez S; Ainciburu M; Vilas-Zornoza A; Martin-Uriz PS; Aguirre-Ruiz P; Ullate-Agote A; Ariceta B; Lamo-Espinosa JM; Acha P; Calvete O; Jimenez T; Molero A; Montoro MJ; Díez-Campelo M; Valcarcel D; Solé F; Alfonso-Pierola A; Ochoa I; Prósper F; Ezponda T; Hernaez M
Nat Commun; 2024 Jun; 15(1):5272. PubMed ID: 38902243
[TBL] [Abstract][Full Text] [Related]
30. Lenalidomide in International Prognostic Scoring System Low and Intermediate-1 risk myelodysplastic syndromes with del(5q): an Italian phase II trial of health-related quality of life, safety and efficacy.
Oliva EN; Latagliata R; Laganà C; Breccia M; Galimberti S; Morabito F; Poloni A; Balleari E; Cortelezzi A; Palumbo G; Sanpaolo G; Volpe A; Specchia G; Finelli C; D'Errigo MG; Rodà F; Alati C; Alimena G; Nobile F; Aloe Spiriti MA
Leuk Lymphoma; 2013 Nov; 54(11):2458-65. PubMed ID: 23432724
[TBL] [Abstract][Full Text] [Related]
31. Lenalidomide therapy for primary myelodysplastic syndromes with isolated del(5q): Determinants of response and survival in a real-world setting.
Singh A; Al-Kali A; Foran JM; Elliott MA; Begna K; Badar T; Khera N; Fleti F; Abdelmagid M; Reichard KK; Ketterling RP; Pardanani A; Gangat N; Tefferi A
Am J Hematol; 2022 Oct; 97(10):E377-E379. PubMed ID: 35959963
[No Abstract] [Full Text] [Related]
32. Lenalidomide treatment of Japanese patients with myelodysplastic syndromes with 5q deletion: a post-marketing surveillance study.
Uno S; Motegi Y; Minehata K; Aoki Y
Int J Hematol; 2023 Oct; 118(4):432-442. PubMed ID: 37493867
[TBL] [Abstract][Full Text] [Related]
33. Lenalidomide Treatment for Lower Risk Nondeletion 5q Myelodysplastic Syndromes Patients Yields Higher Response Rates When Used Before Azacitidine.
Zeidan AM; Al Ali NH; Padron E; Lancet J; List A; Komrokji RS
Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):705-10. PubMed ID: 26440749
[TBL] [Abstract][Full Text] [Related]
34. Genome-wide DNA methylation analysis pre- and post-lenalidomide treatment in patients with myelodysplastic syndrome with isolated deletion (5q).
Hecht A; Meyer JA; Jann JC; Sockel K; Giagounidis A; Götze KS; Letsch A; Haase D; Schlenk RF; Haferlach T; Schafhausen P; Bug G; Lübbert M; Thol F; Büsche G; Schuler E; Nowak V; Obländer J; Fey S; Müller N; Metzgeroth G; Hofmann WK; Germing U; Nolte F; Reinwald M; Nowak D
Ann Hematol; 2021 Jun; 100(6):1463-1471. PubMed ID: 33903952
[TBL] [Abstract][Full Text] [Related]
35. Patients with del(5q) MDS who fail to achieve sustained erythroid or cytogenetic remission after treatment with lenalidomide have an increased risk for clonal evolution and AML progression.
Göhring G; Giagounidis A; Büsche G; Kreipe HH; Zimmermann M; Hellström-Lindberg E; Aul C; Schlegelberger B
Ann Hematol; 2010 Apr; 89(4):365-74. PubMed ID: 19855965
[TBL] [Abstract][Full Text] [Related]
36. Haematological and cytogenetic responses after only 7 days of Lenalidomide in a patient with myelodysplastic syndrome and chromosome 5q deletion.
Hadiji Mseddi S; Kallel F; Kassar O; Elloumi M; Jedidi I; Sennana H; Fenaux P
Leuk Res; 2011 Sep; 35(9):e175-6. PubMed ID: 21658768
[No Abstract] [Full Text] [Related]
37. Response to lenalidomide in myelodysplastic syndromes with del(5q): influence of cytogenetics and mutations.
Mallo M; Del Rey M; Ibáñez M; Calasanz MJ; Arenillas L; Larráyoz MJ; Pedro C; Jerez A; Maciejewski J; Costa D; Nomdedeu M; Diez-Campelo M; Lumbreras E; González-Martínez T; Marugán I; Such E; Cervera J; Cigudosa JC; Alvarez S; Florensa L; Hernández JM; Solé F
Br J Haematol; 2013 Jul; 162(1):74-86. PubMed ID: 23614682
[TBL] [Abstract][Full Text] [Related]
38. Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients.
Pellagatti A; Jädersten M; Forsblom AM; Cattan H; Christensson B; Emanuelsson EK; Merup M; Nilsson L; Samuelsson J; Sander B; Wainscoat JS; Boultwood J; Hellström-Lindberg E
Proc Natl Acad Sci U S A; 2007 Jul; 104(27):11406-11. PubMed ID: 17576924
[TBL] [Abstract][Full Text] [Related]
39. Telomere shortening, clonal evolution and disease progression in myelodysplastic syndrome patients with 5q deletion treated with lenalidomide.
Göhring G; Lange K; Hofmann W; Nielsen KV; Hellström-Lindberg E; Roy L; Morgan M; Kreipe H; Büsche G; Giagounidis A; Schlegelberger B
Leukemia; 2012 Feb; 26(2):356-8. PubMed ID: 21799512
[No Abstract] [Full Text] [Related]
40. Lenalidomide: Myelodysplastic syndromes with del(5q) and beyond.
Talati C; Sallman D; List A
Semin Hematol; 2017 Jul; 54(3):159-166. PubMed ID: 28958290
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
